UZ Leuven

Recently closed projects / recent gesloten projecten / projets récemment fermés / kürzlich geschlossene Projekte

Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide for patients with newly diagnosed glioblastoma (EORTC 26052). Temozolomide is an alkylating agent. Study group/sponsor: EORTC.

Phase 3 study of Enzastaurin versus Lomustine in the treatment of glioblastoma multiforme. Enzastaurin is a potent selective inhibitor of PKCβ; Lomustine is a nitrosourea agent. Study group/sponsor: Eli Lilly.

Phase I/II a study with Cilengitide (EMD121 974) and Temozolomide with concomitant radiation therapy, followed by Cilengitide and Temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma. Cilengitide is an angiogenesis inhibitor, Temozolomide is an alkylating agent. Study group/sponsor: Schering-Plough. Contact: Prof. P. Clement.

A phase III, randomised, parallel group, multi-centre study in recurrent glioblastoma patients to compare the efficacy of Cediranib (Recentin, AZD2171) monotherapy and the combination of Cediranib with Lomustine to the efficacy of Lomustine alone. Study group/sponsor: AstraZeneca. Contact: Prof. P. Clement.

Phase III study with Temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss (EORTC 26033). Temozolomide is an alkylating agent. Study group/sponsor: EORTC. Contact: Prof. P. Clement.

Ongoing projects / lopende projecten / projets actifs / laufende Projekte

Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma (EORTC 26053). Temozolomide is an alkylating agent. Study group/sponsor: EORTC. Contact Prof. P. Clement.

Phase II study of prolonged adjuvant Temozolomide or “stop and go” in glioblastoma patients. Temozolomide is an alkylating agent. Study group/sponsor: /. Contact: Prof. P. Clement.

Phase I/II clinical trial for the treatment of newly diagnosed high grade glioma with tumor vaccination as “add-on therapy” to standard primary treatment (HGG-006). Study group/sponsor: /. Contact: Prof. P. Clement (PI: Prof. S. De Vleesschouwer - Neurosurgery)

Phase III study with Cilengitide in patients with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter. Cilengitide is an angiogenesis inhibitor. Study group/sponsor: Merck. Contact: Prof. P. Clement.

Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in glioblastoma multiforme in elderly patients (EORTC 26062). Study group/sponsor: EORTC. Contact: Prof. P. Clement (PI: Prof. J. Menten)

Phase II study of radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemoirradiation with Temzolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter. Study group/sponsor: EORTC. Contact: Prof. P. Clement.

Planned projects / geplande projecten / projets en développement / geplante Projekte

Phase III study of radiotherapy versus Temozolomide versus radiotherapy with concomitant and adjuvant Temzolomide in newly diagnosed anaplastic oligodendroglioma or anaplastic mixed glioma with chromosomal co-deletions of 1p and 19q (EORTC 26081)). Study group/sponsor: EORTC. Contact: Prof. P. Clement (in collaboration with Prof. J. Menten)

Randomized open-label phase II study of CCNU versus CCNU + Dasatinib in patients with recurrent glioblastoma (EORTC 26083). CCNU (Lomustine) is an alkalyting agent; Dasatinib is an inhibitor of multiple tyrosine kinases. Study group/sponsor: EORTC. Contact: Prof. P. Clement.

Randomized trial assessing the significance of bevacizumab in recurrent grade II and grade III gliomas: TAVAREC. Study group/sponsor: EORTC. Contact: Prof. P. Clement

Phase III Intergroup Study of Radiotherapy versus Temozolomide versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with Newly Diagnosed Anaplastic Oligodendroglioma or Anaplastic Mixed Glioma with Chromosomal co-deletions of 1p and 19q. Study group/sponsor: EORTC. Contact: Prof. P. Clement

• Print
• Stuur door